132,347 Shares in HilleVax, Inc. (NASDAQ:HLVX) Acquired by Stonepine Capital Management LLC

Stonepine Capital Management LLC purchased a new stake in HilleVax, Inc. (NASDAQ:HLVX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 132,347 shares of the company's stock, valued at approximately $274,000. Stonepine Capital Management LLC owned approximately 0.27% of HilleVax as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Millennium Management LLC raised its holdings in shares of HilleVax by 59.6% in the 4th quarter. Millennium Management LLC now owns 411,820 shares of the company's stock valued at $852,000 after acquiring an additional 153,815 shares in the last quarter. Lightspeed Management Company L.L.C. purchased a new stake in shares of HilleVax in the 4th quarter valued at about $4,847,000. Deutsche Bank AG raised its holdings in shares of HilleVax by 32.9% in the 4th quarter. Deutsche Bank AG now owns 420,550 shares of the company's stock valued at $871,000 after acquiring an additional 104,001 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of HilleVax by 51.4% in the 4th quarter. Bank of America Corp DE now owns 231,930 shares of the company's stock valued at $480,000 after acquiring an additional 78,739 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of HilleVax by 2.8% in the 4th quarter. Northern Trust Corp now owns 249,610 shares of the company's stock valued at $517,000 after acquiring an additional 6,916 shares in the last quarter. Hedge funds and other institutional investors own 86.42% of the company's stock.

HilleVax Stock Down 5.9%

Shares of NASDAQ HLVX traded down $0.12 during trading hours on Wednesday, reaching $1.90. 102,462 shares of the stock traded hands, compared to its average volume of 450,804. The company has a market capitalization of $95.27 million, a P/E ratio of -0.61 and a beta of 0.78. HilleVax, Inc. has a 52-week low of $1.34 and a 52-week high of $15.60. The company's 50-day simple moving average is $1.73 and its two-hundred day simple moving average is $1.84.

HilleVax (NASDAQ:HLVX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.25. As a group, sell-side analysts forecast that HilleVax, Inc. will post -2.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "neutral" rating and set a $2.00 price objective on shares of HilleVax in a report on Monday, March 31st. Six research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, HilleVax presently has a consensus rating of "Hold" and a consensus price target of $3.00.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.